Novartis mulling $1.5 mln-$5 mln price range for SMA gene therapy

Novartis Chief Executive Vas Narasimhan said on Wednesday that the Swiss drugmaker is examining a price range for its Zolgensma gene therapy for spinal muscular atrophy (SMA) of between $1.5 million and $5 million per patient.